Genitourinary Cancers

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Daniel J. George, MD, discusses the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

Rana R. McKay, MD, discusses the promising findings from the CheckMate-214 and CABOSUN studies in renal cell carcinoma.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

Toni K. Choueiri, MD, sheds light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the renal cell carcinoma field lies in novel combination regimens.

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Patients with advanced renal cell carcinoma with bone metastases had reductions in bone-turnover markers when treated with radium-223 dichloride and a VEGF inhibitor, although the incidence of symptomatic skeletal events remained high.

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

The FDA’s Oncologic Drugs Advisory Committee voted 6-6 on the potential approval of sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are at high risk of recurrence.

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

Adding enzalutamide to androgen deprivation therapy (ADT) significantly improved metastasis-free survival versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III PROSPER trial.

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.